Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: SENTIEN BIOTECHNOLOGIES, INC.
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2021-08-18 to 2023-02-28
Current total value of award: $510265
Description: SENTIEN BIOTECHNOLOGIES, INC.: R&D OF EX VIVO CELL THERAPY